These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 27903663)

  • 1. Beyond a single pathway: combination therapy in pulmonary arterial hypertension.
    Sitbon O; Gaine S
    Eur Respir Rev; 2016 Dec; 25(142):408-417. PubMed ID: 27903663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.
    Lang IM; Gaine SP
    Eur Respir Rev; 2015 Dec; 24(138):630-41. PubMed ID: 26621977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical considerations for therapies targeting the prostacyclin pathway.
    Farber HW; Gin-Sing W
    Eur Respir Rev; 2016 Dec; 25(142):418-430. PubMed ID: 27903664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New horizons in pulmonary arterial hypertension therapies.
    Galiè N; Ghofrani AH
    Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
    Seferian A; Simonneau G
    Eur Respir Rev; 2013 Sep; 22(129):217-26. PubMed ID: 23997048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary arterial hypertension: tailoring treatment to risk in the current era.
    Gaine S; McLaughlin V
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary hypertension-"state of the art" management in 2012.
    Saxena A
    Indian Heart J; 2012; 64(1):60-73. PubMed ID: 22572428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.
    Sitbon O; Vonk Noordegraaf A
    Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic post-embolic pulmonary hypertension: a new target for medical therapies?
    Delcroix M
    Eur Respir Rev; 2013 Sep; 22(129):258-64. PubMed ID: 23997053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.
    Savale L; Guignabert C; Weatherald J; Humbert M
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.
    Hascoet S; Fournier E; Jaïs X; Le Gloan L; Dauphin C; Houeijeh A; Godart F; Iriart X; Richard A; Radojevic J; Amedro P; Bosser G; Souletie N; Bernard Y; Moceri P; Bouvaist H; Mauran P; Barre E; Basquin A; Karsenty C; Bonnet D; Iserin L; Sitbon O; Petit J; Fadel E; Humbert M; Ladouceur M
    Arch Cardiovasc Dis; 2017 May; 110(5):303-316. PubMed ID: 28286190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
    Kylhammar D; Persson L; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future perspectives in pulmonary arterial hypertension.
    Simonneau G; Hoeper MM; McLaughlin V; Rubin L; Galiè N
    Eur Respir Rev; 2016 Dec; 25(142):381-389. PubMed ID: 27903660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease mechanisms and therapeutic targets in pulmonary hypertension: Key insights from the special issue of vascular pharmacology on pulmonary hypertension.
    Wojciak-Stothard B; Gupte S; Bossone E
    Vascul Pharmacol; 2024 Sep; 156():107415. PubMed ID: 39117158
    [No Abstract]   [Full Text] [Related]  

  • 15. Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies.
    Hansen T; Galougahi KK; Celermajer D; Rasko N; Tang O; Bubb KJ; Figtree G
    Pharmacol Ther; 2016 Sep; 165():50-62. PubMed ID: 27216365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macitentan for the treatment of pulmonary arterial hypertension.
    Spikes L; Williamson T; Satterwhite L
    Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building the case for novel clinical trials in pulmonary arterial hypertension.
    Ryan JJ; Rich JD; Maron BA
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):114-23. PubMed ID: 25604559
    [No Abstract]   [Full Text] [Related]  

  • 18. Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?
    Correale M; Montrone D; Ieva R; Di Biase M; Brunetti ND
    Clin Res Cardiol; 2013 May; 102(5):391-3. PubMed ID: 23389056
    [No Abstract]   [Full Text] [Related]  

  • 19. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
    Udeoji DU; Schwarz ER
    Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
    Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.